GENINCODE PLC (GENI) — Interim results presentation

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the GENINCODE PLC Interim Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted today and publish responses, which is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to CEO, Matthew Walls. Good morning to you. Good morning, Alex, and and good morning, everyone, who who's on the call. So as Alex said, Matthew Walls here, CEO of GENINCODE. I'm here at the Cavendish offices, in the city of London with Paul Forger, the CFO. As Alex said, what we're gonna do is move fairly swiftly through the slides so that we give ourselves plenty of time at the end for some q and a. So if you want to submit any questions, please go ahead and do so. So I'll, start the presentation. We with a bit of delay. We're gonna talk through the interim results, a review of where we are in as a company in The US, in The UK, EU. We'll have an update on ROKA, and then we'll finish on a financial summary and outlook. I won't spend too long on this, but I hope most people are aware of what we do, who we are. We're involved in the genetics of heart disease. Importantly, this is a missing piece in terms of the standard of care, and it's coming very quickly to be recognized as being perhaps the most important piece for recognizing those individuals in the population most at risk of heart disease in the future. We're scaling ...